Amedisys Inc (AMED) - Net Assets

Latest as of June 2025: $1.27 Billion USD

Based on the latest financial reports, Amedisys Inc (AMED) has net assets worth $1.27 Billion USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.22 Billion) and total liabilities ($940.48 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AMED tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $1.27 Billion
% of Total Assets 57.55%
Annual Growth Rate 23.05%
5-Year Change 45.54%
10-Year Change 187.49%
Growth Volatility 102.05

Amedisys Inc - Net Assets Trend (1993–2024)

This chart illustrates how Amedisys Inc's net assets have evolved over time, based on quarterly financial data. See Amedisys Inc (AMED) defensive interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Amedisys Inc (1993–2024)

The table below shows the annual net assets of Amedisys Inc from 1993 to 2024. For live valuation and market cap data, see Amedisys Inc market capitalisation.

Year Net Assets Change
2024-12-31 $1.18 Billion +5.37%
2023-12-31 $1.12 Billion +1.19%
2022-12-31 $1.11 Billion +13.34%
2021-12-31 $976.32 Million +20.42%
2020-12-31 $810.74 Million +26.38%
2019-12-31 $641.51 Million +32.92%
2018-12-31 $482.63 Million -6.54%
2017-12-31 $516.43 Million +11.99%
2016-12-31 $461.14 Million +12.35%
2015-12-31 $410.44 Million +3.19%
2014-12-31 $397.76 Million +6.79%
2013-12-31 $372.48 Million -18.00%
2012-12-31 $454.23 Million -12.67%
2011-12-31 $520.15 Million -40.87%
2010-12-31 $879.72 Million +19.47%
2009-12-31 $736.34 Million +30.99%
2008-12-31 $562.12 Million +25.52%
2007-12-31 $447.82 Million +23.03%
2006-12-31 $364.01 Million +89.00%
2005-12-31 $192.60 Million +29.72%
2004-12-31 $148.47 Million +188.86%
2003-12-31 $51.40 Million +203.01%
2002-12-31 $16.96 Million +402.76%
2001-12-31 $3.37 Million +275.73%
2000-12-31 $-1.92 Million +81.00%
1999-12-31 $-10.10 Million +12.75%
1998-12-31 $-11.58 Million -239.87%
1997-12-31 $8.28 Million +83.88%
1996-12-31 $4.50 Million +4.72%
1995-12-31 $4.30 Million +95.45%
1994-12-31 $2.20 Million +15.79%
1993-12-31 $1.90 Million --

Equity Component Analysis

This analysis shows how different components contribute to Amedisys Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 131759.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings $791.16 Million 69.73%
Common Stock $38.00K 0.00%
Other Components $343.35 Million 30.26%
Total Equity $1.13 Billion 100.00%

Amedisys Inc Competitors by Market Cap

The table below lists competitors of Amedisys Inc ranked by their market capitalization.

Company Market Cap
GZ Port
SHG:601228
$3.32 Billion
China Railway Construction Heavy Industry Corp Ltd
SHG:688425
$3.32 Billion
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
$3.33 Billion
Fattal 1998 Holdings Ltd
TA:FTAL
$3.33 Billion
Avicopter PLC
SHG:600038
$3.32 Billion
Star Health and Allied Insurance Company Limited
NSE:STARHEALTH
$3.32 Billion
Loomis AB ser. B
ST:LOOMIS
$3.32 Billion
Shenzhen Yan Tian Port Holdings Co Ltd
SHE:000088
$3.32 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Amedisys Inc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,066,514,000 to 1,134,541,000, a change of 68,027,000 (6.4%).
  • Net income of 43,231,000 contributed positively to equity growth.
  • Share repurchases of 6,152,000 reduced equity.
  • Other factors increased equity by 30,948,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $43.23 Million +3.81%
Share Repurchases $6.15 Million -0.54%
Other Changes $30.95 Million +2.73%
Total Change $- 6.38%

Book Value vs Market Value Analysis

This analysis compares Amedisys Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.94x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 66.44x to 2.94x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 $1.52 $100.99 x
1994-12-31 $1.42 $100.99 x
1995-12-31 $1.77 $100.99 x
1996-12-31 $1.26 $100.99 x
1997-12-31 $1.65 $100.99 x
1998-12-31 $-2.86 $100.99 x
1999-12-31 $-2.47 $100.99 x
2000-12-31 $-0.33 $100.99 x
2001-12-31 $0.31 $100.99 x
2002-12-31 $1.41 $100.99 x
2003-12-31 $3.83 $100.99 x
2004-12-31 $8.22 $100.99 x
2005-12-31 $9.05 $100.99 x
2006-12-31 $16.33 $100.99 x
2007-12-31 $17.01 $100.99 x
2008-12-31 $20.87 $100.99 x
2009-12-31 $26.48 $100.99 x
2010-12-31 $30.82 $100.99 x
2011-12-31 $18.08 $100.99 x
2012-12-31 $15.13 $100.99 x
2013-12-31 $11.91 $100.99 x
2014-12-31 $12.10 $100.99 x
2015-12-31 $12.40 $100.99 x
2016-12-31 $13.64 $100.99 x
2017-12-31 $15.02 $100.99 x
2018-12-31 $14.33 $100.99 x
2019-12-31 $19.41 $100.99 x
2020-12-31 $24.32 $100.99 x
2021-12-31 $28.25 $100.99 x
2022-12-31 $32.20 $100.99 x
2023-12-31 $32.72 $100.99 x
2024-12-31 $34.33 $100.99 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Amedisys Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 3.81%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 1.84%
  • • Asset Turnover: 1.10x
  • • Equity Multiplier: 1.89x
  • Recent ROE (3.81%) is below the historical average (9.32%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 -5.26% -0.71% 3.26x 2.26x $-290.00K
1995 20.93% 2.39% 3.27x 2.67x $470.00K
1996 0.42% 0.04% 2.73x 3.91x $-413.16K
1997 -14.43% -2.19% 2.38x 2.76x $-2.02 Million
1998 0.00% -65.30% 0.86x 0.00x $-23.70 Million
1999 0.00% 1.33% 2.31x 0.00x $2.32 Million
2000 0.00% 7.02% 2.18x 0.00x $6.56 Million
2001 162.77% 4.89% 2.31x 14.40x $5.06 Million
2002 4.43% 0.58% 2.22x 3.44x $-944.30K
2003 16.36% 5.90% 1.54x 1.80x $3.27 Million
2004 13.81% 9.03% 1.14x 1.35x $5.66 Million
2005 15.63% 7.89% 1.12x 1.77x $10.84 Million
2006 10.51% 7.07% 1.17x 1.27x $1.85 Million
2007 14.57% 9.33% 1.19x 1.31x $20.42 Million
2008 15.44% 7.30% 1.11x 1.91x $30.55 Million
2009 18.48% 8.98% 1.29x 1.59x $62.32 Million
2010 12.82% 6.89% 1.26x 1.48x $24.79 Million
2011 -73.71% -26.01% 1.71x 1.65x $-434.35 Million
2012 -18.48% -5.62% 2.04x 1.62x $-128.82 Million
2013 -25.84% -7.70% 1.72x 1.95x $-133.40 Million
2014 3.22% 1.06% 1.80x 1.69x $-26.94 Million
2015 -0.74% -0.24% 1.87x 1.67x $-43.98 Million
2016 8.10% 2.59% 1.96x 1.60x $-8.76 Million
2017 5.88% 1.98% 1.89x 1.58x $-21.23 Million
2018 24.78% 7.18% 2.32x 1.49x $71.19 Million
2019 19.80% 6.49% 1.55x 1.97x $62.79 Million
2020 22.69% 8.86% 1.32x 1.94x $102.69 Million
2021 22.45% 9.44% 1.19x 1.99x $115.94 Million
2022 11.28% 5.34% 1.12x 1.88x $13.45 Million
2023 -0.91% -0.44% 1.09x 1.93x $-116.40 Million
2024 3.81% 1.84% 1.10x 1.89x $-70.22 Million

Industry Comparison

This section compares Amedisys Inc's net assets metrics with peer companies in the Medical Care Facilities industry.

Industry Context

  • Industry: Medical Care Facilities
  • Average net assets among peers: $392,935,463
  • Average return on equity (ROE) among peers: 10112.15%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Amedisys Inc (AMED) $1.27 Billion -5.26% 0.74x $3.32 Billion
Acadia Healthcare Company Inc (ACHC) $432.55 Million 4.72% 1.27x $1.52 Billion
Addus HomeCare Corporation (ADUS) $34.58 Million 11.64% 2.93x $1.69 Billion
agilon health Inc (AGL) $661.02 Million -39.73% 1.63x $264.44 Million
Airsculpt Technologies Inc (AIRS) $79.29 Million -10.41% 1.65x $354.84 Million
AMN Healthcare Services Inc (AMN) $284.13 Million 12.09% 1.26x $624.22 Million
American Shared Hospital Service (AMS) $11.83 Million 169.54% 1.28x $8.87 Million
American Oncology Network Inc. (AONC) $24.17K 90834.23% 1.03x $292.48 Million
Ardent Health Partners, Inc. (ARDT) $1.52 Billion 13.82% 2.26x $1.33 Billion
Astrana Health Inc (ASTH) $510.64 Million 13.50% 0.70x $1.90 Billion

About Amedisys Inc

NASDAQ:AMED USA Medical Care Facilities
Market Cap
$3.32 Billion
Market Cap Rank
#4729 Global
#1568 in USA
Share Price
$100.99
Change (1 day)
+0.01%
52-Week Range
$95.96 - $100.99
All Time High
$314.16
About

Amedisys, Inc. provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment provides a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services,… Read more